Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO

This article was originally published in The Tan Sheet

Executive Summary

A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says
Advertisement

Related Content

FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
FDA Considers “New Paradigm” To Facilitate Third Class Of Drugs
CDER Director Sees Behind-The-Counter Switches As Best Bet
CDER Director Sees Behind-The-Counter Switches As Best Bet
CDER Director Sees Behind-The-Counter Switches As Best Bet
Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
Plan B Ruling: Little Commercial Impact, Big Policy Implications
Congressmen Call On GAO To Update Behind-The-Counter Class Investigation
Congressmen Call On GAO To Update Behind-The-Counter Class Investigation

Topics

Advertisement
UsernamePublicRestriction

Register

PS102746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel